

Gene and/or mutant	Protein Function	NTD Type(s)	Penetrance	References
<i>Efna5</i>	Cell Adhesion & Interaction	EX or SF+EX	20% (F:M=2:1)	Holmberg et al. (2000), Abdul-Aziz et al. (2009)**
<i>Epha7</i>	Cell Adhesion & Interaction	EX	25%	Holmberg et al. (2000), Abdul-Aziz et al. (2009)**
<i>Epha2tm1Jrui/+Epha4rb-2J/+ double heterozygous</i>	Cell Adhesion & Interaction	SBO or Ex	28% or 16%	Abdullah et al. (2017)
<i>Frem1</i>	Cell Adhesion & Interaction	EX	2%	Varnum & Fox (1981); Smyth et al. (2004)
<i>Frem2 (my mutant; my-F11 ENU mutant)</i>	Cell Adhesion & Interaction	EX	5%- most	Carter (1959); Jadeja et al. (2005); Timmer et al. (2005)
<i>Gja1, Gja5 (Cx43, Cx40; digenic)</i>	Cell Adhesion & Interaction	EX	17% -/-,-/-; 5% +/-,-/-; 2% +/-,-/-	Lo et al. (1997); Simon et al. (2004)
<i>Grip1(eb mutant)</i>	Cell Adhesion & Interaction	EX	30%	Swiergiel et al. (2000); Takamiya et al. (2004)
<i>Hspg2</i>	Cell Adhesion & Interaction	EX	6%	Arikawa-Hirasawa et al. (1999)
<i>Itga3, Itga6 (digenic)</i>	Cell Adhesion & Interaction	EX	45%	De Arcangelis et al. (1999); Thorsteinsdottir et al. (1995)
<i>Itgb1 (a isoform)</i>	Cell Adhesion & Interaction	EX or SBA	some	Baudoin et al. (1998); Ohyama et al. (1997)
<i>Conditional Itgb1-/- in surface ectoderm</i>	Cell Adhesion & Interaction	SBA	56%	Mole et al. (2020)
<i>Conditional Itgb1-/- in neural ectoderm</i>	Cell Adhesion & Interaction	EX or SBA	9% or 9%	Mole et al. (2020)
<i>Lama5 (ENU)</i>	Cell Adhesion & Interaction	EX	no data	Zohn et al. (2005)
<i>Lama5 null</i>	Cell Adhesion & Interaction	EX	60%	Miner et al. (1998)
<i>Lmnb1**</i>	Cell Adhesion & Interaction	Modifier of ct (Grhl3)	N/A	De Castro et al. (2012)
<i>Piga</i>	Cell Adhesion & Interaction	EX + SF	75% in heterozygotes (-/- die by GD10)	Nozaki et al. (1999)
<i>Rgma</i>	Cell Adhesion & Interaction	EX	50%	Niederkofler et al. (2004)
<i>Myo10 null</i>	Cell Adhesion & Interaction	EX or CRS	73% or 18%	Heimsath et al. (2017)
<i>Gadd45a</i>	Cell cycle	EX	10%	Hollander et al. (1999)
<i>Nap112 chimera</i>	Cell cycle	EX	some	Rogner et al. (2000)
<i>Nls1**</i>	Cell cycle	EX		Regeling et al. (2011)
<i>Phactr4 (humdy mutant) (defect in PP1 binding)</i>	Cell cycle	EX	100%	Kim et al. (2007)
<i>Rad9b **</i>	Cell cycle	EX	20% in heterozygotes (-/- die by GD10)	Leloup et al. (2010)
<i>Terc</i>	Cell cycle	SF, EX, SBA	10% SF, 15% EX, 5% SBA	Herrera et al. (1999)
<i>Tsc1</i>	Cell cycle	EX	15%	Wilson et al. (2005)
<i>Tsc2</i>	Cell cycle	EX	50%	Kobayashi et al. (1999)
<i>Xrcc2</i>	Cell cycle	EX	30%	Deans et al. (2000)
<i>Enpp2 (ATX)</i>	Cell migration	open neural tube	100%	Fotopoulou et al. (2010), van Meeteren et al. (2006)
<i>Plxnb2**</i>	Cell migration	EX +/- SBA	90% EX, 45% SBA or CT	Deng et al. (2007); Friedel et al. (2007)
<i>Sema4c**</i>	Cell migration	EX	35%	Maier et al. (2010)
<i>Ambra1</i>	Cell survival	EX +/- SBA	on B6: 15% EX, 65% SBA, 20% EX+SBA (on mixed: 50% EX, 5% SBA, 30% EX+SBA)	Fimia et al. (2007)
<i>Apaf1 (fog mutant)</i>	Cell survival	SBA +/- SF+rostral EX	40% SBA; 10% SF+EX	Harris et al. (1997); Honarpour et al. (2001)
<i>Apaf1 null</i>	Cell survival	SF+rostral EX; hindbrain EX	35% SF+EX; 35% hindbrain EX	Cecconi et al. (1998); Yoshida et al. (1998)
<i>Bcl10</i>	Cell survival	hindbrain EX	30%	Ruland et al. (2001)
<i>Casp3</i>	Cell survival	SF+rostral EX or hindbrain EX	100%	Houde et al. (2004); Urase et al. (2003)
<i>Casp9</i>	Cell survival	hindbrain EX	some	Hakem et al. (1998)
<i>Chuk, Ikkkb (digenic)</i>	Cell survival	hindbrain EX	70%	Li et al. (2000)
<i>Cyts (Cyt c; null for apoptotic function)</i>	Cell survival	EX	25%	Hao et al. (2005)
<i>Enpp2 (ATX)</i>	Cell survival	open neural tube	100%	Fotopoulou et al. (2010), van Meeteren et al. (2006)
<i>Map3k4 null</i>	Cell survival	EX +/- SBA	20% EX+SBA, 35% EX, 35% SBA	Chi et al. (2005)
<i>Map3k4 partial function</i>	Cell survival	EX +/- SBA	50% EX +/- SBA	Abell et al. (2005)
<i>Mapk8, Mapk9 (Jnk1, Jnk2; digenic)</i>	Cell survival	hindbrain EX	100% -/-, -/- (25% -/-, +/-)	Kuan et al. (1999); Sabapathy et al. (1999)
<i>Mdm4</i>	Cell survival	"improper neural tube closure"	all?	Migliorini et al. (2002)
<i>Nls1**</i>	Cell survival	EX	¾ females, 1/6 males	Regeling et al. (2011)
<i>Por (CYPOR)</i>	Cell survival	EX	some EX	Shen et al. (2002)
<i>Ptdsr</i>	Cell survival	EX	2-15%	Li et al. (2003); Bose et al. (2004)
<i>Rad9b **</i>	Cell survival	EX	20% in heterozygotes (-/- die by GD10)	Leloup et al. (2010)
<i>Sphk1, Sphk2 (digenic)</i>	Cell survival	EX	20%	Mizugishi et al. (2005)
<i>Terc</i>	Cell survival	SF, EX, SBA	10% SF, 15% EX, 5% SBA	Herrera et al. (1999)
<i>Traf4</i>	Cell survival	SBA	some	Masson et al. (1998); Regnier et al. (2002)
<i>Traf6</i>	Cell survival	EX	35%	Lomaga et al. (2000)
<i>Txn2</i>	Cell survival	EX	all	Nonn et al. (2003)
<i>Xrcc2</i>	Cell survival	EX	30%	Deans et al. (2000)

<i>Apob null</i>	Cellular transport	EX	all alive past GD10	Farese et al. (1995)
<i>Apob truncated</i>	Cellular transport	EX	30%	Homanics et al. (1995)
<i>Atp2c1 (Spc1)</i>	Cellular transport	EX	all	Okunade et al. (2007)
<i>Atp2c1 (Spc1) 1D mutant</i>	Cellular transport	EX or SBO or CRS	100% or 100% or 2.4%	Brown et al. (2018)
<i>Fpn1 (Slc40a1) (hypomorph)</i>	Cellular transport	EX +/- SBA	100% EX, 1% SBA on C3HxC57BL/6; 0% on 129	Zohn et al. (2007)
<i>Mttp</i>	Cellular transport	EX	all	Raabe et al. (1998)
<i>Ptpn9 (Meg2)</i>	Cellular transport	EX +/- SBA	98% EX; 50% SBA	Wang et al. (2005)
<i>Rab23 (opb mutant)</i>	Cellular transport	EX +/- SBA	2-100% EX; 1-2 % SBA	Gunther et al. (1994)
<i>Rab23 (opb2 ENU mutant)</i>	Cellular transport	EX +/- SBA	no data	Kasarskis et al. (1998); Eggenschwiler et al. (2001)
<i>Sec24b</i>	Cellular transport	CRS	100%	Merte et al. (2010)
<i>Snx1, Snx2 (digenic)</i>	Cellular transport	EX	20% in +/-; -/-	Griffin et al. (2005)
<i>Snx13</i>	Cellular transport	EX	100%	Zheng et al. (2006)
<i>Trpm6</i>	Cellular transport	EX	~30% (some SBO)	Walder et al. (2009)
<i>Cobl hypomorph; Lp/+ (digenic)</i>	Cilia	EX	20%	Carroll et al. (2003)
<i>Dvl2</i>	Cilia	thoracic SBA+EX	3%	Klingensmith et al. (1996); Hamblet et al. (2002)
<i>Arl13b (hennin ENU mutant)**</i>	Cilia	EX + SBA	all?	Homer et al. (2011); Caspary et al. (2007)
<i>B9d1**</i>	Cilia	EX	6%	Dowdle et al. (2011)
<i>Bbs4</i>	Cilia	EX	15%	Ross et al. (2005)
<i>Tctn2**</i>	Cilia	EX	100% (on 129xC57BL/6)	Sang et al. (2011)
<i>Dync2h1 (lln mutant)</i>	Cilia	EX	50%	Huangfu & Anderson (2005)
<i>Dync2l1</i>	Cilia	EX	all	Rana et al. (2004)
<i>Ift172 (wim mutant)</i>	Cilia	EX	all?	Huangfu et al. (2003)
<i>Traf3ip1**</i>	Cilia	EX	some (% not given)	Berbari et al. (2011)
<i>brom1 (ENU#10)**</i>	Cilia	EX	some?	Ko et al. (2010); Zohn et al. (2005)
<i>C2cd3 (Hty mutant)</i>	Cilia	EX	30%	Hoover et al. (2008)
<i>Cluap1**</i>	Cilia	"unclosed NT"	60%?	Botilde et al. (2013); Pasek et al. (2012)
<i>Ift122</i>	Cilia	EX	all?	Cortellino et al. (2009)
<i>Ift140 (cauli mutant)**</i>	Cilia	EX (+SF) +/- SBA	100% EX(+SF?), some SBA	Miller et al. (2013)
<i>Kif3b</i>	Cilia	EX	all?	Nonaka et al. (1998)
<i>Inpp5e</i>	Cilia	EX	30%	Jacoby et al. (2009)
<i>Fuz</i>	Cilia	EX	"few"	Gray et al. (2009); Heydeck et al. (2009); Heydeck and Liu (2011)
<i>Intu</i>	Cilia	EX	30%	Zeng et al. (2010)
<i>Mks1 (krc mutant)</i>	Cilia	EX	30%	Weatherbee et al. (2009)
<i>Stil-/-</i>	Cilia	Cranial NTD	all?	Izraeli et al. (1999)
<i>Tmem67**</i>	Cilia	EX, frontal encephalocele	25% EX, 25% encephalocele	Abdelhamed et al. (2013)
<i>Tmem107**</i>	Cilia	EX	xxx	Christopher et al. (2012)
<i>vl mutant</i>	Cilia	SBA	40%	Wilson & Wyatt (1992)
<i>Sec24b</i>	Polarity	CRS	100%	Merte et al. (2010)
<i>Cdx1, Cdx2** (digenic)</i>	Polarity	CRS	100%	Savory et al. (2011)
<i>Celsr1 (Scy & Crsh mutants)</i>	Polarity	CRS	100%	Curtin et al. (2003)
<i>Cthrc1-/-; Vangl2-Lp/+ (digenic)</i>	Polarity	EX	all	Durmus et al. (2006); Yamamoto et al. (2008)
<i>Dvl1, Dvl2 (digenic)</i>	Polarity	CRS	95%	Hamblet et al. (2002)
<i>Dvl2+/-; Dvl3-/- (digenic)</i>	Polarity	CRS	some	Etheridge et al. (2008)
<i>Dvl2-/-; Dvl3+/- (digenic)</i>	Polarity	CRS	~100%	Etheridge et al. (2008)
<i>Fat1, Fat4**</i>	Polarity	EX	75%	Saburi et al. (2012)
<i>Fat1, Fjx1**</i>	Polarity	EX	50%	Saburi et al. (2012)
<i>Fat1-/-</i>	PCP	EX	40%	Badouel et al. (2015)
<i>Fzd3, Fzd6 (digenic)</i>	Polarity	CRS	most	Wang et al. (2006)
<i>Ptk7</i>	Polarity	CRS, occasional SBA	all	Lu et al. (2004); Paudyal et al. (2010)**
<i>Scrib (Crc mutant)</i>	Polarity	CRS	100%	Murdoch et al. (2001, 2003)
<i>Sdc4-/-; Lp/+**</i>	Polarity	SBA	55%	Escobedo et al. (2013)
<i>Sestd1**</i>	Polarity	caudal regression syndrome +/- SBA (like Dact1)	"partially penetrant"	Yang et al. (2013)
<i>Sfrp1, Sfrp2, Sfrp5 (trigenic)</i>	Polarity	CRS	100%	Satoh et al. (2008)
<i>Smurf1, Smurf2</i>	Polarity	CRS	65%	Narimatsu et al. (2009)
<i>Vangl2 (Lp mutant)</i>	Polarity	CRS, occasional SBA in Lp/+	100%	Murdoch et al. (2001a); Kibar et al. (2001)

<i>Lp, Crc mutants (Vangl2, Scrib) digenic, heterozygous</i>	Polarity	CRS or SBA	55% CRS, 5% SBA	Murdoch et al. (2001b)
<i>Lp, Crsh mutants (Vangl2, Celsr1) digenic, heterozygous</i>	Polarity	CRS	no data	Copp et al. (2003b)
<i>Lp, Ptk7 (digenic, heterozygous)</i>	Polarity	SBA	95%	Lu et al. (2004)
<i>Vangl1+/-, Vangl2-Lp/+ (digenic)</i>	Polarity	CRS	60%	Torban et al. (2008)
<i>Vangl2-Lp/+, Dvl2-/- (digenic)</i>	Polarity	CRS	100%	Wang et al. (2006)
<i>Vangl2-Lp/+, Dvl3+/- (digenic)</i>	Polarity	CRS, EX	some	Etheridge et al. (2008)
<i>Vangl2-Lp/+, Sec24b+/- (digenic)</i>	Polarity	SBA	70%	Merte et al. (2010)
<i>Vangl2-Lp/+, Sfrp1-/-, Sfrp2+/-, Sfrp5-/- (4 genes)</i>	Polarity	SBA	60%	Satoh et al. (2008)
<i>Dlgh1**</i>	Polarity	CRS	7% (plus open eyelids, CP, cochlear defects)	Rivera et al. (2013)
<i>Wnt5a**</i>	Polarity	CRS or EX	5%	Yamaguchi et al. (1999); Qian et al. (2007); Schleiffarth et al. (2007); He et al. (2008)
<i>Dact1**</i>	Polarity	caudal regression syndrome (not NTD) +/- SBA	95% caudal regression, 15-20% SBA	Suriben et al. (2009), Wen et al. (2010a)
<i>Abl1</i>	Cytoskeleton	no closure	all	Rakeman & Anderson (2006)
<i>Abl1, Abl2 (digenic)</i>	Cytoskeleton	EX	some	Koleske et al. (1998)
<i>Cfl1</i>	Cytoskeleton	no closure	all	Gurmiak et al. (2005)
<i>Dlc1</i>	Cytoskeleton	EX	all?	Durkin et al. (2005)
<i>Enah, Pfn1(-/-, +/-) (digenic)</i>	Cytoskeleton	EX	50%	Lanier et al. (1999)
<i>Enah, Vasp (digenic)</i>	Cytoskeleton	EX, some SF+EX	EX	Menzies et al. (2004)
<i>Griff1 (p190RhoGAP)</i>	Cytoskeleton	EX	30%	Brouns et al. (2000)
<i>Marcks</i>	Cytoskeleton	EX	30% in females; 15% in males	Stumpo et al. (1995); Blackshear et al. (1996)
<i>Marcks11 (Mlp)</i>	Cytoskeleton	EX +/- SBA	55-100% EX; 0-15% SBA	Chen et al. (1996); Wu et al. (1996)
<i>Pald</i>	Cytoskeleton	EX	100%	Luo et al. (2005)
<i>Pip5k1c</i>	Cytoskeleton	EX	100%	Wang et al. (2007)
<i>Rac1-/-, Grhl3-Cre/+ (digenic) (Rac1 is conditional null in expression domain of Grhl3)</i>	Cytoskeleton	EX +/- SBA	60% EX, 85% SBA	Camerer et al. (2010); Sugihara et al. (1998)
<i>Rac1-/-, Grhl3-Cre/+ (digenic) (Rac1 is conditional null in expression domain of Grhl3)</i>	Cytoskeleton	EX +/- SBA	60% EX, 85% SBA	Camerer et al. (2010); Sugihara et al. (1998)
<i>Conditional Rac1ff or fl- with Pax3Cre/+</i>	Cytoskeleton	SBA(curlied tail) or EX	76% or 8%	Rolo et al. (2016)
<i>Conditional Rac1ff or fl- with Grhl3Cre/+</i>	Cytoskeleton	SBA(curlied tail) or EX	89% or 25%	Rolo et al. (2016)
<i>Shroom3</i>	Cytoskeleton	EX +/- SF, +/- SBA	100% EX; 85% SF; 25% SBA	Hildebrand & Soriano (1999)
<i>Snx13</i>	Cytoskeleton	EX	100%	Zheng et al. (2006)
<i>Vcl</i>	Cytoskeleton	SF + EX	all	Xu et al. (1998)
<i>Alkbh1**</i>	Epigenetic Regulator	EX	2% (10% of the 20% alive on GD10-11)	Ougland et al. (2012)
<i>Cecr2</i>	Epigenetic Regulator	EX	0-75%	Banting et al. (2005)
<i>Dnmt3b</i>	Epigenetic Regulator	EX	most or all	Okano et al. (1999)
<i>Dnmt3l (+/- embryos in -/- dam)</i>	Epigenetic Regulator	EX	15%	Hata et al. (2002)
<i>Fbx10**</i>	Epigenetic Regulator	EX	50%	Fukuda et al. (2011)
<i>Hdac4</i>	Epigenetic Regulator	EX	some	Vega et al. (2004)
<i>Jarid1b**</i>	Epigenetic Regulator	EX	5%	Albert et al. (2013)
<i>Kat2a (Gcn5) (conditional KO, hypomorph)</i>	Epigenetic Regulator	EX	15% in fn/fn; 100% in fn/null on 129, 20% on C57BL/6	Bu et al. (2007); Lin et al. (2008); Xu et al. (2000)
<i>Ppm1g**</i>	Epigenetic Regulator	EX	30%	Foster et al. (2013)
<i>Sirt1</i>	Epigenetic Regulator	EX	some	Cheng et al. (2003)
<i>Smarca4 heterozygotes</i>	Epigenetic Regulator	EX	15% in heterozygotes	Bultman et al. (2000); Randazzo et al. (1994)
<i>Smarcc1 (Baf155)** hypomorph</i>	Epigenetic Regulator	EX	80% in homozygotes (heterozygotes normal)	Harmacek et al. (2013 or 2014)
<i>Suz12+/-</i>	Epigenetic Regulator	SB	incomplete penetrance	Miro et al. (2009)
<i>Smarcc1 heterozygotes</i>	Epigenetic Regulator	EX	20% in heterozygotes	Kim et al. (2001)
<i>Utx, Uty** (homologous)</i>	Epigenetic Regulator	EX	all	Westead et al. (2012), Shpargel et al. (2012)
<i>Amr**</i>	Metabolism	EX or CRS	82% EX, 5% CRS	Narisawa et al. (2011)
<i>Gldc/GT2/GT2</i>	Metabolism	Primarily EX, some SBA or CRS	53%	Leung et al. (2017)
<i>Folr1 null</i>	Metabolism	no closure	all	Piedrahita et al. (1999)
<i>Folr1 partial rescue by folate</i>	Metabolism	EX	5-30%	Piedrahita et al. (1999); Saitsu et al. (2003); Spiegelstein et al. (2004a, 2004b)
<i>Mthfd11**</i>	Metabolism	EX or CRS	55% EX, 5% CRS (1/26)	Momb et al. (2013)

Gene	Category	Genotype	Frequency	Notes	References
<i>Mtrr hypomorph**</i>	Metabolism	EX	5% in grandprogeny of a maternal grandfather or grandmother <i>gt/+</i> ; independent of embryo genotype		Padmanabhan et al. (2013)
<i>Nat2</i>	Metabolism	EX	2%		Wakefield et al. (2007, 2008)
<i>Pip5k1c</i>	Metabolism	EX	100%		Wang et al. (2007)
<i>Por (CYPOR)</i>	Metabolism	EX	some EX		Shen et al. (2002)
<i>Conditional Slc19a-/- in whole embryo, or neural crest cell, or yolk sac</i>	Metabolism	EX	71.4% or 34.6% or 33.3%		Toriyama et al. (2017)
<i>Slc25a19</i>	Metabolism	EX	all		Lindhurst et al. (2006)
<i>Slc25a32gt/gt</i>	Metabolism	Majority Ex and some CRS	100%		Kim et al. (2018)
<i>Aldh1a2</i>	Signaling	Craniorachischisis	all		Niederreither et al. (1999)
<i>Alx3**</i>	Signaling	EX (+/-SF)	60% EX, some SF		Lakhwani et al. (2010)
<i>Apob null</i>	Signaling	EX	all alive past GD10		Farese et al. (1995)
<i>Apob truncated</i>	Signaling	EX	30%		Homanics et al. (1995)
<i>Arnt</i>	Signaling	SF, EX, SF+EX	40%		Kozak et al. (1997)
<i>Axin1(Fu mutant)</i>	Signaling	EX or SBA	10%EX, 25%SBA		Theiler & Gluecksohn-Waelsch (1956); Zeng et al. (1997)
<i>Birc5 (survivin) conditional null in endothelial cells</i>	Signaling	EX	30%		Zwerts et al. (2007)
<i>Bmp2 conditional null, flox(neo), hypomorph</i>	Signaling	EX	25% in flox/null		Singh et al. (2008)
<i>Bmp2 null</i>	Signaling	EX	60% in heterozygote (-/- die by GD10)		Castriano & Mishina (2009)
<i>Bmp5, Bmp7 (digenic)</i>	Signaling	EX	all		Solloway & Robertson (1999)
<i>Brca1 hypomorph</i>	Signaling	EX	10%		Xu et al. (2001)
<i>Brca1 null</i>	Signaling	EX +/-or SBA	40%		Gowen et al. (1996)
<i>Calr</i>	Signaling	EX	15%		Rauch et al. (2000)
<i>Cart1</i>	Signaling	EX	65-100%		Zhao et al. (1996)
<i>Cited2</i>	Signaling	EX	60-80%		Dunwoodie et al. (1998); Bamforth et al. (2001); Barbera et al. (2002)
<i>Crebbp</i>	Signaling	EX	all		Tao et al. (1998)
<i>Csk</i>	Signaling	EX	all		Imamoto et al. (1993); Nada et al. (1993)
<i>Csnk2a1</i>	Signaling	EX	>90%		Lou et al. (2008); Seldin et al. (2008)
<i>Ctnnb1 (b catenin conditional KO)**</i>	Signaling	SBA	100%		Zhao et al. (2014)
<i>Ctnnbip1 (ICAT)</i>	Signaling	EX+SF	15%		Satoh et al. (2004)
<i>Cyp26a1</i>	Signaling	SBA +/- EX	most SBA, some EX		Abu-Abed et al. (2001, 2003)
<i>Deaf1</i>	Signaling	EX	80%		Hahm et al. (2004)
<i>Dlx5</i>	Signaling	EX	30%		Depew et al. (1999)
<i>Edg2</i>	Signaling	EX	5%		Contos et al. (2000)
<i>Ep300</i>	Signaling	EX	100%		Yao et al. (1998)
<i>Epor</i>	Signaling	hindbrain EX	all?		Tsai et al. (2006)
<i>F2r, F2r1 (Par1, Par2) (digenic)</i>	Signaling	EX +/-or SBA	35% EX, rare SBA		Camerer et al. (2010), Copp & Greene (2010)
<i>Fdft1</i>	Signaling	EX	60%		Tozawa et al. (1999)
<i>Fgfr1 (a isoform)</i>	Signaling	SBA	all		Xu et al. (1999)
<i>Fgfr1 chimera</i>	Signaling	SBA	70%		Deng et al. (1997); Yamaguchi et al. (1992)
<i>Fgfr2C342Y</i>	Signaling	EX or SBA	63% or <1%		Peskett et al. (2017)
<i>Fkbp1a</i>	Signaling	EX	10%		Shou et al. (1998)
<i>Fkbp8 hypomorph</i>	Signaling	SBA	100%		Finnell et al. (2006); Bulgakov et al. (2004)
<i>Fkbp8 null**</i>	Signaling	SBA +/- EX	100% SBA; some EX		Shirane et al. (2008); Shirane-Kitsuji and Nakayama (2014)
<i>Foxb1</i>	Signaling	EX	5%		Labosky et al. (1997)
<i>Fzd3</i>	Signaling	EX	25%		Borello et al. (1999); Wang et al. (2002)
<i>Gli3 (Xt, Bph, Pdn mutants)</i>	Signaling	EX	20-60%		Johnson (1969); Hui & Joyner (1993); Sasaki et al. (1997)
<i>Gnaz-/-, Grhl3-Cre/+ (digenic) (Gnaz is conditional null in domain of Grhl3; the 4 other Gi/o/z genes inactivated in Grhl3 domain by pertussis toxin)</i>	Signaling	EX +/-or SBA	20% EX, 40% SBA		Camerer et al. (2010); Hendry et al. (2000)
<i>Gnb1</i>	Signaling	EX	40%		Okae & Iwakura (2010)
<i>Gpr161 (v1 mutant, hypomorph)</i>	Signaling	SBA	40%		Korstanje et al. (2008); Matteson et al. (2008)
<i>Grhl2 (Axd mutant, hypermorph)**</i>	Signaling	SBA	40-100% (F:M=1:1)		Brouns et al. (2011); Essien et al. (1990)
<i>Grhl2 (null)**</i>	Signaling	EX+SF, SBA	100% EX+SF, 90% SBA (15% EX+SF in heterozygote)		Brouns et al. (2011); Rifat et al. (2010); Werth et al. (2010)
<i>Grhl21Nis (ENU mutant, truncated)**</i>	Signaling	EX+SF	100%		Pyrgaki et al. (2011)
<i>Grhl3 null</i>	Signaling	SBA +/- EX	100% SBA, 2% EX		Ting et al. (2003); Auden et al. (2006)

<i>Gtf2i</i>	Signaling	EX	60% in null, 15% in +/-	Enkhmandakh et al. (2009)
<i>Gtf2ird1</i>	Signaling	EX	10% in null, 2% in +/-	Enkhmandakh et al. (2009)
<i>Hectd1 (opm mutant)</i>	Signaling	EX	90% in opm/opm, 5% in opm/+	Zohn et al. (2007); Kasarskis et al. (1998); Sarkar and Zohn (2012)
<i>Hes1</i>	Signaling	SF+EX	70%	Ishibashi et al. (1995); Lee et al. (2005a)
<i>Hic1</i>	Signaling	EX	35%	Carter et al. (2000)
<i>Hif1a</i>	Signaling	EX	all	Iyer et al. (1998)
<i>Hipk1, Hipk2 (digenic)</i>	Signaling	EX (F:M=2:1)	50% -/-, -/-; 10% +/-, -/-; 5% -/-, +/-	Isono et al. (2006); Aikawa et al. (2006)
<i>Hmx1 (dmbo mutant)</i>	Signaling	EX	25%	Munroe et al. (2009)
<i>Hspg2</i>	Signaling	EX	6%	Arikawa-Hirasawa et al. (1999)
<i>Inka1</i>	Signaling	EX	5%	Reid et al. (2010)
<i>Itpk1 (hypomorph)</i>	Signaling	EX +/or SBA	10%	Wilson et al. (2009)
<i>Jarid2 (jmj mutant)</i>	Signaling	EX	50%	Takeuchi et al. (1995)
<i>Klkb1</i>	Signaling	No closure	all	Ylikorkala et al. (2001)
<i>Lmo4</i>	Signaling	EX	10-50%	Hahm et al. (2004); Tse et al. (2004); Lee et al. (2005b)
<i>Lrp2**</i>	Signaling	EX	40%	Kur et al. (2014)
<i>Lrp6</i>	Signaling	EX +/or SBA	50% EX +/or SBA	Pinson et al. (2000)
<i>Lrp6 (Cd mutant, hypermorph)</i>	Signaling	EX	20% (F:M=2:1)	Carter et al. (2005)
<i>Lrp6 (rs mutant, hypomorph)</i>	Signaling	SBA	some	Kokubu et al. (2004)
<i>Lrp6Skax26~Jus hypermorph**</i>	Signaling	Curly tail	10-50% in -/-; 5-10% in +/-	Allache et al. (2013)
<i>Luzp1</i>	Signaling	EX	40%	Hsu et al. (2008)
<i>Map3k7</i>	Signaling	hindbrain EX	most female mosaic hemizygotes: 5% EX, 65%	Shim et al. (2005)
<i>Med12</i>	Signaling	EX or SBA or CRS	EX+SBA, 30% CRS	Rocha et al. (2010)
<i>Men1</i>	Signaling	EX	20% on 129, 0% on C57BL/6	Bertolino et al. (2003); Lemos et al. (2009)
<i>Mib2</i>	Signaling	EX	10-50%	Wu et al. (2007)
<i>Msgn1</i>	Signaling	SBA	all?	Yoon & Wold (2000)
<i>Msx1, Msx2 (digenic)</i>	Signaling	EX +/or SBA	some	Ishii et al. (2005); Lallemand et al. (2005)
<i>Mttp</i>	Signaling	EX	all	Raabe et al. (1998)
<i>Ndst1</i>	Signaling	EX, SBA	5% EX, 5% SBA	Pallerla et al. (2007)
<i>Neurog2</i>	Signaling	EX	5%	Fode et al. (1998); Ma et al. (1998)
<i>Nf1</i>	Signaling	EX	15% females; 0% males	Lakkis et al. (1999)
<i>Nog</i>	Signaling	EX	0-100% EX	McMahon et al. (1998); Stottmann et al. (2006)
<i>Nuak1, Nuak2** (digenic)</i>	Signaling	EX + SF + SBA	100%	Ohmura et al. (2012)
<i>Nuak2**</i>	Signaling	EX	40%	Ohmura et al. (2012)
<i>Numb</i>	Signaling	EX (die by GD11)	all	Zhong et al. (2000); Zilian et al. (2001)
<i>Ovol2</i>	Signaling	No closure	all	Mackay et al. (2006)
<i>p38IP (drey ENU mutant)</i>	Signaling	EX, SBA	55% EX, 15% SBA	Zohn et al. (2006)
<i>Patz1**</i>	Signaling	EX	25%	Valentino et al. (2013)
<i>Pax2</i>	Signaling	EX	100%	Torres et al. (1996); Puschel et al. (1992)
<i>Pax3 (Sp mutant)</i>	Signaling	EX +/or SBA	50-100% EX; 25-100% SBA	Auerbach (1954); Goulding et al. (1991); Machado et al. (2001)
<i>Pax3 (Sp2H X-ray mutant)</i>	Signaling	EX +/or SBA	35-75% EX, 85% SBA	Fleming & Copp (2000); Machado et al. (2001)
<i>Pax3 (Spd mutant, hypomorph)</i>	Signaling	EX +/or SBA	0-25% EX; 60-100% SBA	Moase & Trasler (1989); Machado et al. (2001)
<i>Pitx2</i>	Signaling	EX	5%	Gage et al. (1999)
<i>Prkaca, Prkacb (digenic)</i>	Signaling	EX	25% in -/-; +/-	Huang et al. (2002)
<i>Ptch1 (partial rescue by Ptch1 transgene, strong MT promoter)</i>	Signaling	EX	some	Milenkovic et al. (1999); Ybot-Gonzalez et al. (2002)
<i>Ptch1 (partial rescue by Ptch1 transgene, weak MT promoter)</i>	Signaling	EX+CRS	all	Milenkovic et al. (1999)
<i>Ptch1 null</i>	Signaling	No closure	all	Goodrich et al. (1997)
<i>Ptch-/- and Cdon-/-</i>	Signaling	Ex	all	Camp et al. (2014)
<i>Ptch-/-, Cdon-/- and Boc-/-</i>	Signaling	Ex	all	Camp et al. (2014)
<i>Ptfn11 chimera</i>	Signaling	SBA	60%	Saxton & Pawson (1999); Feng et al. (1993)
<i>Rac1-/-, Grhl3-Cre/+ (digenic) (Rac1 is conditional null in expression domain of Grhl3)</i>	Signaling	EX +/or SBA	60% EX, 85% SBA	Camerer et al. (2010); Sugihara et al. (1998)
<i>Rara, Rarg (digenic)</i>	Signaling	EX + SF	45%	Lohnes et al. (1994); Ang et al. (1997)
<i>Rbpsuh</i>	Signaling	EX	most	Oka et al. (1995)
<i>Rere (Atr2, om mutant)</i>	Signaling	EX	100%	Zoltewicz et al. (2004)

<i>Rybp</i> heterozygotes	Signaling	EX	15% in heterozygotes	Pirity et al. (2005)
<i>Sall1</i> truncated	Signaling	EX	40%	Kiefer et al. (2003)
<i>Sall2</i>	Signaling	EX	10% on 129; 0% on C57BL/6	Bohm et al. (2008)
<i>Sall4</i> heterozygotes	Signaling	EX	5% in heterozygotes	Sakaki-Yumoto et al. (2006)
<i>Scarb1</i> **	Signaling	EX	44% in females, 20% in males	Santander et al. (2012)
<i>Sfrp1, Sfrp2</i> (digenic)	Signaling	hydromelia (SB covered by nonneural ectoderm)	90%	Misra & Matise (2010)
<i>Ski</i>	Signaling	EX	5-85% EX	Berk et al. (1997); Colmenares et al. (2002); Lyons et al. (1994)
<i>Smad5</i>	Signaling	EX	some	Chang et al. (1999)
<i>Sp8</i> (Igl mutant, hypomorph)	Signaling	EX	5%	McNeish et al. (1990); Bell et al. (2003)
<i>Sp8</i> null	Signaling	EX +/- SF, + SBA	90% EX (some SF), 100% SBA	Bell et al. (2003)
<i>Spint2</i> (HA12)	Signaling	EX, SBA	95% EX, 10% SBA	Szabo et al. (2009)
<i>Ss18</i> (Syt)	Signaling	open neural tube, EX	50%	Kimura et al. (2009)
<i>Sufu</i>	Signaling	No closure	all	Cooper et al. (2005); Svard et al. (2006);
<i>T</i> (Tc/tw5 mutant)	Signaling	SBA	100%	Park (1989); Greene et al. (1998)
<i>Tcfap2a</i> (Ap2)	Signaling	SF+EX	100%	Schorle et al. (1996); Zhang et al. (1996); Kohlbecker et al. (2002)
<i>Tcof1</i> +/-	Signaling	EX	5-100% in heterozygotes	Dixon & Dixon (2004)
<i>Tead2</i>	Signaling	EX	30% in -/- dam, 10% in +/- dam 2% in F1 of 129/Svx/C57BL/6; 20% in BC1 to C57BL/6	Kaneko et al. (2007)
<i>Tgfr1</i> (exon 3 deletion, truncated)	Signaling	EX		Jin et al. (2006); Kuang et al. (2006)
<i>Tiam1</i> **	Signaling	EX	30%	Yoo et al. (2012)
<i>Trp53</i> (p53)	Signaling	EX	20-30% females; 0-1% males	Armstrong et al. (1995); Sah et al. (1995)
<i>p53</i> -/-; <i>Bim</i> +/- and <i>p53</i> -/-; <i>Bim</i> -/-	Signaling	EX and few SBA	100% in female	Delbridge et al. (2019)
<i>Trp53bp2Δ3/Δ3</i>	Signaling	CRS or EX or SBA	8%-46% in different genetic background	Zak et al. (2016)
<i>Tulp3</i>	Signaling	EX +/- or SBA	70% EX; 40% SBA	Ikeda et al. (2001)
<i>Tulp3</i> (hhkr mutant) truncated, hypomorph	Signaling	EX +/- or SBA	35% EX, 65% SBA	Patterson et al. (2009)
<i>Twist1</i>	Signaling	EX	all	Chen & Behringer (1995); Soo et al. (2002); Bildsoe et al. (2013)
<i>Wnt3a</i> (vt mutant, hypomorph)	Signaling	SBA	some vt/null	Greco et al. (1996)
<i>Ybx1</i>	Signaling	EX	30%	Lu et al. (2005)
<i>Yyl</i> heterozygotes	Signaling	EX	15% in heterozygotes	Donohoe et al. (1999)
<i>Zfhx1a</i>	Signaling	EX or SBA	4% EX, 2% SBA	Takagi et al. (1998)
<i>Zfp361</i>	Signaling	EX	some	Stumpo et al. (2004)
<i>Zfp568</i> (chato mutant)	Signaling	open neural tube	100%	Garcia-Garcia et al. (2008)
<i>Zic2</i> hypomorph	Signaling	SBA +/- EX	100% SBA, 10% EX	Nagai et al. (1997, 2000)
<i>Zic2Ku</i> (ENU mutant, null)	Signaling	EX (+SBA?)	100% EX (+SBA)?	Elms et al. (2003)
<i>Zic3</i> (bn mutant)	Signaling	EX	25%	Carrel et al. (2000); Klootwijk et al. (2000); Purandare et al. (2002); Lickert et al. (2005)
<i>Zic5</i>	Signaling	EX	15%	Inoue et al. (2004)
<i>Alx3</i> **	Transcription & translation	EX (+/-SF)	60% EX, some SF	Lakhwani et al. (2010)
<i>Arnt</i>	Transcription & translation	SF, EX, SF+EX	40%	Kozak et al. (1997)
<i>Brca1</i> hypomorph	Transcription & translation	EX	10%	Xu et al. (2001)
<i>Brca1</i> null	Transcription & translation	EX +/- or SBA	40%	Gowen et al. (1996)
<i>Cart1</i>	Transcription & translation	EX	65-100%	Zhao et al. (1996)
<i>Cited2</i>	Transcription & translation	EX	60-80%	Dunwoodie et al. (1998); Bamforth et al. (2001); Barbera et al. (2002)
<i>Crebbp</i>	Transcription & translation	EX	all	Tao et al. (1998)
<i>Csnk2a1</i>	Transcription & translation	EX	>90%	Lou et al. (2008); Seldin et al. (2008)
<i>Deaf1</i>	Transcription & translation	EX	80%	Hahm et al. (2004)
<i>Dlx5</i>	Transcription & translation	EX	30%	Depew et al. (1999)
<i>Dnajb6</i> (Mrj)	Transcription & translation	EX	25%	Watson et al. (2009)
<i>Eif2c2</i> (Ago2)	Transcription & translation	EX	50%	Liu et al. (2004)
<i>Ep300</i>	Transcription & translation	EX	100%	Yao et al. (1998)
<i>Foxb1</i>	Transcription & translation	EX	5%	Labosky et al. (1997)
<i>Gli3</i> (Xt, Bph, Pdn mutants)	Transcription & translation	EX	20-60%	Johnson (1969); Hui & Joyner (1993); Sasaki et al. (1997)
<i>Grhl2</i> (Axd mutant, hypermorph)**	Transcription & translation	SBA	40-100% (F:M=1:1) 100% EX+SF, 90% SBA (15% EX+SF in heterozygote)	Brouns et al. (2011); Essien et al. (1990)
<i>Grhl2</i> (null)**	Transcription & translation	EX+SF, SBA		Brouns et al. (2011); Rifat et al. (2010); Werth et al. (2010)
<i>Grhl21Nis</i> (ENU mutant, truncated)**	Transcription & translation	EX+SF	100%	Pyrgaki et al. (2011)

<i>Grhl3 null</i>	Transcription & translation	SBA +/- EX	100% SBA, 2% EX	Ting et al. (2003); Auden et al. (2006)
<i>Gtf2i</i>	Transcription & translation	EX	60% in null, 15% in +/-	Enkhmandakh et al. (2009)
<i>Gtf2ird1</i>	Transcription & translation	EX	10% in null, 2% in +/-	Enkhmandakh et al. (2009)
<i>Hes1</i>	Transcription & translation	SF+EX	70%	Ishibashi et al. (1995); Lee et al. (2005a)
<i>Hic1</i>	Transcription & translation	EX	35%	Carter et al. (2000)
<i>Hif1a</i>	Transcription & translation	EX	all	Iyer et al. (1998)
<i>Hipk1, Hipk2 (digenic)</i>	Transcription & translation	EX (F:M=2:1)	50% -/-, -/-; 10% +/-, -/-; 5% -/-, +/-	Isono et al. (2006); Aikawa et al. (2006)
<i>Hmx1 (dmbo mutant)</i>	Transcription & translation	EX	25%	Munroe et al. (2009)
<i>Jarid2 (jmj mutant)</i>	Transcription & translation	EX	50%	Takeuchi et al. (1995)
<i>Lmo4</i>	Transcription & translation	EX	10-50%	Hahm et al. (2004); Tse et al. (2004); Lee et al. (2005b)
<i>Luzp1</i>	Transcription & translation	EX	40%	Hsu et al. (2008)
<i>Med12</i>	Transcription & translation	EX or SBA or CRS	female mosaic hemizygotes: 5% EX, 65% EX+SBA, 30% CRS	Rocha et al. (2010)
<i>Men1</i>	Transcription & translation	EX	20% on 129, 0% on C57BL/6	Bertolino et al. (2003); Lemos et al. (2009)
<i>Msgn1</i>	Transcription & translation	SBA	all?	Yoon & Wold (2000)
<i>Msx1, Msx2 (digenic)</i>	Transcription & translation	EX +/- SBA	some	Ishii et al. (2005); Lallemand et al. (2005)
<i>Neurog2</i>	Transcription & translation	EX	5%	Fode et al. (1998); Ma et al. (1998)
<i>Nup50</i>	Transcription & translation	EX	100%	Smitherman et al. (2000)
<i>Patz1**</i>	Transcription & translation	EX	25%	Valentino et al. (2013)
<i>Pax2</i>	Transcription & translation	EX	100%	Torres et al. (1996); Puschel et al. (1992)
<i>Pax3 (Sp mutant)</i>	Transcription & translation	EX +/- SBA	50-100% EX; 25-100% SBA	Auerbach (1954); Goulding et al. (1991); Machado et al. (2001)
<i>Pax3 (Sp2H X-ray mutant)</i>	Transcription & translation	EX +/- SBA	35-75% EX, 85% SBA	Fleming & Copp (2000); Machado et al. (2001)
<i>Pax3 (Spd mutant, hypomorph)</i>	Transcription & translation	EX +/- SBA	0-25% EX; 60-100% SBA	Moase & Trasler (1989); Machado et al. (2001)
<i>Pitx2</i>	Transcription & translation	EX	5%	Gage et al. (1999)
<i>Rbpsuh</i>	Transcription & translation	EX	most	Oka et al. (1995)
<i>Rere (Atr2, om mutant)</i>	Transcription & translation	EX	100%	Zoltewicz et al. (2004)
<i>Rpl24 (Bst mutant)</i>	Transcription & translation	EX	30% in Bst/+ (Bst/Bst die in utero)	Rice et al. (1995); Oliver et al. (2004)
<i>Rybp heterozygotes</i>	Transcription & translation	EX	15% in heterozygotes	Pirity et al. (2005)
<i>Sall1 truncated</i>	Transcription & translation	EX	40%	Kiefer et al. (2003)
<i>Sall2</i>	Transcription & translation	EX	10% on 129; 0% on C57BL/6	Bohm et al. (2008)
<i>Sall4 heterozygotes</i>	Transcription & translation	EX	5% in heterozygotes	Sakaki-Yumoto et al. (2006)
<i>Ski</i>	Transcription & translation	EX	5-85% EX	Berk et al. (1997); Colmenares et al. (2002); Lyons et al. (1994)
<i>Sp8 (Igl mutant, hypomorph)</i>	Transcription & translation	EX	5%	McNeish et al. (1990); Bell et al. (2003)
<i>Sp8 null</i>	Transcription & translation	EX +/- SF, + SBA	90% EX (some SF), 100% SBA	Bell et al. (2003)
<i>Ss18 (Syf)</i>	Transcription & translation	open neural tube, EX	50%	Kimura et al. (2009)
<i>T (Tc/tw5 mutant)</i>	Transcription & translation	SBA	100%	Park (1989); Greene et al. (1998)
<i>Tcfap2a (Ap2)</i>	Transcription & translation	SF+EX	100%	Schorle et al. (1996); Zhang et al. (1996); Kohlbecker et al. (2002)
<i>Tcof1+/-</i>	Transcription & translation	EX	5-100% in heterozygotes	Dixon & Dixon (2004)
<i>Tead2</i>	Transcription & translation	EX	30% in -/- dam, 10% in +/- dam	Kaneko et al. (2007)
<i>Trim71 (Min41)</i>	Transcription & translation	EX	100%	Maller Schulman et al. (2008)
<i>Trim71 (truncated, hypomorph)</i>	Transcription & translation	EX	55%	Maller Schulman et al. (2008)
<i>Trp53 (p53)</i>	Transcription & translation	EX	20-30% females; 0-1% males	Armstrong et al. (1995); Sah et al. (1995)
<i>p53-/-;Bim+/- and p53-/-;Bim-/-</i>	Transcription & translation	EX and few SBA	100% in female	Delbridge et al. (2019)
<i>Twist1</i>	Transcription & translation	EX	all	Chen & Behringer (1995); Soo et al. (2002); Bildsoe et al. (2013)
<i>Ybx1</i>	Transcription & translation	EX	30%	Lu et al. (2005)
<i>Yyl heterozygotes</i>	Transcription & translation	EX	15% in heterozygotes	Donohoe et al. (1999)
<i>Zfx1a</i>	Transcription & translation	EX or SBA	4% EX, 2% SBA	Takagi et al. (1998)
<i>Zfp361l</i>	Transcription & translation	EX	some	Stumpo et al. (2004)
<i>Zfp568 (chato mutant)</i>	Transcription & translation	open neural tube	100%	Garcia-Garcia et al. (2008)
<i>Zic2 hypomorph</i>	Transcription & translation	SBA +/- EX	100% SBA, 10% EX	Nagai et al. (1997, 2000)
<i>Zic2(m1Nisw)</i>				Ying Paper
<i>Zic2Ku (ENU mutant, null)</i>	Transcription & translation	EX (+SBA?)	100% EX (+SBA?)	Elms et al. (2003)
<i>Zic3 (bn mutant)</i>	Transcription & translation	EX	25%	Carrel et al. (2000); Klootwijk et al. (2000); Purandare et al. (2002); Lickert et al. (2005)
<i>Zic5</i>	Transcription & translation	EX	15%	Inoue et al. (2004)
<i>Grhl2 (ENU)</i>	Unknown Function	EX	no data	Zohn et al. (2005)
<i>aln (ENU mutant)</i>	Unknown Function	EX or SBA	low frequency	Herron et al. (2002)

<i>ct mutant (Grl3 hypomorph?)</i>	Unknown Function	SBA +/- EX	10-20% SBA (1:1=female:male); 0-4% EX (4:1=female:male)	van Straaten & Copp (2001); Greene & Copp (1997); Cogram et al. (2002)
<i>Dbf mutant</i>	Unknown Function	SF or EX+SF	80% SF, 20% EX+SF	Lyon et al. (1996)
<i>Ds mutant</i>	Unknown Function	EX or SBA	0-55% EX, 0-5% SBA	Hummel (1958); Crosby et al. (1992)
<i>excp (ENU mutant)</i>	Unknown Function	EX	25%	Herron et al. (2002)
<i>Exen1, Exen2, Exen3, Exen4 (SELH/Bc strain)</i>	Unknown Function	EX or cleft cerebellum	5-30% EX depending on maternal diet (2:1=female:male); 5-10% cleft cerebellum	Juriloff et al. (1989, 2001, 2006); Harris & Juriloff (2005)
<i>exma mutant</i>	Unknown Function	EX or SF+EX	85% EX, 5% SF+EX	Cunningham et al. (2002)
<i>Gw (ENU mutant)</i>	Unknown Function	EX	no data	Bogani et al. (2004)
<i>I11Jus15 (ENU)</i>	Unknown Function	EX	10%	Kile et al. (2003)
<i>Line-3P (ENU)**</i>	Unknown Function	EX	30%	Marean et al. (2011)
<i>Mtu (ENU mutant)</i>	Unknown Function	EX	no data	Bogani et al. (2004)
<i>nt mutant</i>	Unknown Function	EX	some	Melloy et al. (1998)
<i>sobp ENU mutant</i>	Unknown Function	EX	no data	Garcia-Garcia et al. (2005)
<i>Th1-Ex1, Th1-Ex2 in haplolethal deletions</i>	Unknown Function	EX	50% (hemizygotes)	Howell et al. (2005)
<i>Ts mutant heterozygotes</i>	Unknown Function	EX	5-20% in Ts/+	Ishijima et al. (1998)
<i>tuft mutant**</i>	Unknown Function	EX or cephalocele	10% EX; 10% cephalocele	Fong et al. (2014)